Research programme: CD8 Treg modulators - Mozart Therapeutics
Alternative Names: Research programme: CD8 T regulatory cell modulators - Mozart TherapeuticsLatest Information Update: 28 Jun 2026
At a glance
- Originator Mozart Therapeutics
- Class Anti-inflammatories; Antihyperglycaemics
- Mechanism of Action CD8 positive T lymphocyte modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammatory bowel diseases; Type 1 diabetes mellitus
Most Recent Events
- 28 Jun 2026 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 28 Jun 2026 No recent reports of development identified for preclinical development in Inflammatory-bowel-diseases in USA
- 28 Jun 2026 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA